Introduction: Postpartum iron deficiency anemia is common in India as a consequence of post partum hemorrhage. Recent studies have evaluated the use of parenteral iron as a better tolerated treatment modality. Compared with oral iron supplements, parenteral iron is associated with a rapid rise in serum ferritin and hemoglobin and improved maternal fatigue scores in the postpartum period. Parenteral iron may be considered for the treatment of postpartum anemia. Objective: The objective of the study was to evaluate the efficacy, safety, and tolerability of intravenous ferric carboxymaltose, in women with postpartum anemia. Study Design: A clinical observational study was undertaken in a tertiary care hospital, 50 women within six weeks of delivery with Hb≥6g/dl and ≤10 g /dl received 1000 mg of ferrium, over 15 minutes or less, repeated weekly to a calculated replacement dose (maximum 2500 mg) . Hemoglobin and serum ferritin levels were recorded prior to treatment and on day 21after completion of treatment. Results: Ferric carboxymaltose-treated subjects achieved a hemoglobin rise of ≥ 3 g/dL quickly, and attained higher serum ferritin levels in a short time period (21 days). It was also associated with good patient compliance, and shorter treatment period. Drug-related adverse events occurred less frequently with ferric carboxymaltose. The only noted disadvantage was that it was more expensive when compared to other iron preparations. Conclusion: Intravenous ferric carboxymaltose is safe and well tolerated with good efficacy and good patient compliance in the treatment of postpartum iron deficiency anemia.